4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of AsthmaBusiness Wire • 12/13/21
4D pharma says asthma live biotherapeutic shows ‘promising' early signs of clinical activityProactive Investors • 12/13/21
4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021Business Wire • 12/09/21
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics SummitBusiness Wire • 10/12/21
4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021Business Wire • 09/15/21
4D pharma to will display two posters showcasing positive data for lead cancer asset at leading oncology conferenceProactive Investors • 09/15/21
4D pharma to Participate in Upcoming Virtual Investor Conferences in SeptemberBusiness Wire • 09/09/21
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021Business Wire • 08/02/21
4D Pharma to present cancer candidate at European Society for Medical Oncology CongressProactive Investors • 08/02/21
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-TBusiness Wire • 07/06/21
4D pharma says pre-clinical research points to the potential of its discovery to enhance cancer CAR-T therapiesProactive Investors • 07/06/21
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program UpdateBusiness Wire • 06/04/21
4D pharma PLC has completed recruitment for first part of its phase I/II asthma trialProactive Investors • 06/04/21
4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome CandidateBenzinga • 05/24/21